MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Dicyclomine hydrochloride is used in the treatment of functional disturbances of GI motility such as irritable bowel syndrome. As with other antispasmodics, dicyclomine has limited efficacy in the treatment of these disorders and should be used only if other measures (e.g., diet, sedation, counseling, amelioration of environmental factors) have been of little or no benefit. Although dicyclomine has also been used in combination with phenobarbital in the treatment of irritable bowel syndrome, attempts to substantiate claims of efficacy for fixed combinations that include an antispasmodic and phenobarbital have generally failed and these combinations are generally considered as lacking substantial evidence of efficacy in the treatment of this condition.
Dicyclomine has been used alone and in combination with phenobarbital in the treatment of infant colic and acute enterocolitis, but the drug alone and the combination are generally considered as lacking substantial evidence of efficacy in the treatment of these conditions. Infant colic is considered a benign, self-limiting condition that tends to resolve spontaneously and not require medical treatment.
Dosage and Administration
Dicyclomine hydrochloride is usually administered orally. When oral therapy is not feasible, the drug may be administered by IM injection. IM injection of the drug may produce local irritation and/or transient sensation of lightheadedness. Oral therapy should replace IM therapy as soon as possible, and IM therapy should not be used for longer than 1 or 2 days. Dicyclomine should not be administered by IV or subcutaneous injection. The oral solutions should be diluted with an equal volume of water just prior to administration.
The only oral dosage of dicyclomine hydrochloride clearly shown to be effective in adults is 40 mg 4 times daily. Because this dosage is associated with a substantial incidence of adverse effects, the usual initial dosage should be 20 mg 4 times daily. Depending on the patient's response, dosage should be increased during the first week of therapy to 40 mg 4 times daily unless adverse effects limit upward titration. If an adequate response is not obtained within 2 weeks or adverse effects limit dosage to less than 80 mg daily, the drug should be discontinued.
The safety of dosages of 80-160 mg daily for longer than 2 weeks has not been established. Abuse and/or dependence on dicyclomine for its anticholinergic effects has been reported rarely.
The recommended IM dosage of dicyclomine hydrochloride for adults is 20 mg 4 times daily.
The pharmacokinetics of dicyclomine hydrochloride have not been fully determined.
Dicyclomine hydrochloride is absorbed rapidly from the GI tract, achieving peak plasma concentrations within 1-1.5 hours after oral administration of the drug (about 1, 1.1, and 1.5 hours for the solution, capsules, and tablets, respectively). Comparison of the areas under the plasma concentration-time curves (AUCs) for single, 40-mg doses of dicyclomine hydrochloride oral solution and IM injection indicates that the relative oral bioavailability of the drug is about 67% of that following IM injection. The drug is absorbed slightly faster following IM injection than after oral administration. The bioavailabilities (as determined by AUC) of dicyclomine hydrochloride oral solution, capsules, and tablets are equivalent.
The apparent volume of distribution of dicyclomine is reportedly 3.65 L/kg.
Plasma concentrations of dicyclomine hydrochloride appear to decline in a biphasic manner. The half-life of the drug in the initial distribution phase (t½α) is about 1.8 hours and the half-life in the terminal elimination phase (t½β) is about 9-10 hours. Although the metabolic fate of dicyclomine has not been determined, about 80% of a dose is eliminated in urine and about 10% in feces.